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Background: The safety of an infant formula containing a new mixture of the prebiotics galacto-oligosaccharides
(GOS) and fructo-oligosaccharide (FOS) and the probiotic Lactobacillus reuteri needs to be evaluated.
Methods: Healthy term infants in Singapore were randomly assigned (using computer-generated allocation
sequences) to receive exclusively an experimental infant formula containing L. reuteri, GOS (5.50 g/L), and FOS
(0.36 g/L) or a control formula containing only L. reuteri from enrollment (7–14 days of age) to 4 months of age.
The primary objective of this trial was to demonstrate that weight change between birth and 4 months of age in
infants fed the experimental formula was not inferior to World Health Organization (WHO) Child Growth standards.
The non-inferiority margin was −0.5 standard deviations (SD). The secondary objectives were to compare changes
in anthropometric measurements (weight, length, body mass index, and head circumference), digestive tolerance,
stool bacterial counts, urinary D- and L- lactate concentrations, and adverse events in the two formula groups.
Results: The intention-to-treat (ITT) population included all randomized infants stratified by gender, (experimental
group, N = 68 and control group, N = 72). The per-protocol (PP) population included 61 infants in the experimental
and 62 infants in the control groups. The change in weight-for-age z-score between birth and 4 months was +0.93
(95% confidence interval [CI]: +0.63 to +1.23) SD in the experimental group and +0.92 (95% CI: +0.62 to +1.22) SD
in the control group in the PP population, indicating non-inferior weight gain in both formulas groups compared
with WHO standards. The ITT population had similar results. Liquid stools occurred more frequently in the experimental
compared with the control group and median bifidobacteria, lactobacilli, and enterococci counts were higher in
the experimental group (p < 0.05). Other secondary outcomes were not significantly different between groups.
Conclusions: Infant formula containing L. reuteri + GOS/FOS supports normal growth and is safe.
Trial registration: ClinicalTrial.gov: NCT01010113
Keywords: Infant formula, Probiotic, Lactobacillus reuteri, Galacto-oligosaccharides, Fructo-oligosaccharide, Growth,
Safety* Correspondence: le_ye_LEE@nuhs.edu.sg
1Department of Neonatology, National University Health System, NUHS
Tower Block 1E Kent Ridge Road, Singapore 119228, Singapore
2Department of Pediatrics, Yong Loo Lin School of Medicine, National
University of Singapore, Singapore, Singapore
Full list of author information is available at the end of the article
© 2015 Lee et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Lee et al. Maternal Health, Neonatology, and Perinatology  (2015) 1:9 Page 2 of 10Background
Human milk is a superior source of nutrition for infants.
It contains nutrients and other bioactive components
that have beneficial health effects, which are manifested
partly by the reduced susceptibility of breast-fed infants
to infections [1-4].
Understanding and replicating some of the beneficial
properties of human milk is an important goal in infant
formula development. However, progress in this area has
been incremental due to the complexity of human milk,
our limited knowledge of its bioactive components, and
technical challenges in reproducing some of its proper-
ties. Nonetheless, it is known that part of the benefits of
human milk derive from its ability to stimulate the de-
velopment of a gut microbiota in infants rich in bifido-
bacteria and lactobacilli. The initial inocula for infants’
microbiota occurs via the passive transmission of these
bacteria from the birth canal and through human milk
[5-7]. Human milk also contains a large array of undi-
gestible oligosaccharides, which can selectively stimulate
the growth of bifidobacteria and lactobacilli in the infant
gut [7,8]. In addition to their bifidogenic properties, the
non-digestible oligosaccharides in human milk have other
beneficial health effects; for example, some of the sialic
acid-containing oligosaccharides have similar structures to
glycans on receptors in the gut epithelium that can bind
pathogens. Thus, these human milk oligosaccharides bind
directly to pathogens and act as decoys thereby, reducing
infections [1,9].
Addition of probiotic Bifidobacterium or Lactobacillus
strains as well as non-digestible oligosaccharides (prebi-
otics) to infant formulas allows at least some mimicking
of human milk. Various bacterial strains have been used in
the development of probiotc-containing infant formulas.
Lactobacillus reuteri, a probiotic whose safety and toler-
ance in both term and preterm infants has been demon-
strated in clinical studies [10-14] may also have potential
beneficial effects in the management of colic [15-17], in
preventing infections, and in reducing diarrhea [18-21].
The prebiotics trans galacto-oligosaccharides (GOS)
and fructo-oligosaccharide (FOS) are safe and have pre-
viously been shown to increase bifidobacteria counts
and decrease counts of harmful pathogens like Escheri-
chia coli and Clostridium in the gut of infants [22,23].
Furthermore, a prebiotic mixture (8 g/L) containing 90%
GOS and 10% FOS was reported to reduce infections in
infants during the first 6 months of life [24]. The fermen-
tation products of prebiotics, mainly acetate, butyrate, and
propionate, are thought to have immuno-modulatory ef-
fects that could, at least in theory, lead to better protection
against infections [25].
The mixture of probiotics and prebiotics, synbiotics,
has potential synergistic effects [26], which can be used
to improve the functional properties of infant formulas.The current study was performed to evaluate the safety
of a formula containing L. reuteri and GOS and FOS in
healthy term infants.Population and methods
Study design
This was a single center, prospective, parallel-group,
double-blind, randomized, controlled, non-inferiority
trial conducted at the Department of Neonatology of
the National University Hospital, Singapore. It took place
between November 2009 and June 2011. The trial was
performed in accordance with the Helsinki Declaration
and complied with Good Clinical Practices as laid out
in the International Conference on Harmonization
guidelines. It was approved by the institution’s Ethics
Committee (the National Healthcare Group, Domain
Specific Review Board), and parents/legal guardians
signed informed consent forms before infants were en-
rolled in the study.
The primary objective of this trial was to demonstrate
that weight gain between birth and 4 months in healthy
term infants fed a formula containing either L. reuteri
and GOS/FOS or L. reuteri only was not inferior to the
World Health Organization (WHO) child growth stan-
dards [27].
The secondary objective was to demonstrate that daily
weight gain in infants fed the formula containing experi-
mental formula with L. reuteri and GOS/FOS was not in-
ferior to that of infants fed the control formula containing
L. reuteri using the non-inferiority margin of −3.0 g/day,
the criterion recommended by the American Academy
of Pediatrics (AAP) [28]. Other secondary objectives
were to compare length, head circumference, and body
mass index (BMI) between the two formula groups, as-
sess digestive tolerance, quantify stool bacterial counts
and urinary D- and L- lactate concentrations, and assess
adverse events (AEs).Study population
Newborn infants visiting the National University Hospital
of Singapore were recruited for the study if their mothers
had elected not to breast feed after hospital discharge.
Inclusion criteria further required babies to be healthy,
singleton at birth, full term (≥37 weeks and ≤42 weeks of
gestation), ≤14 days old, and have a birth weight between
2500 g and 4500 g.
Infants were excluded from the trial if they had any of
the following exclusion criteria: congenital illness or mal-
formation that could affect normal growth, significant
pre- or post-natal disease, re-hospitalization for >2 days
during the first 14 days of life for reasons other than neo-
natal jaundice, or participation in another clinical trial
prior to the beginning of the current one. Additionally,
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comply with the study requirements were also excluded.
Study formulas and blinding
Formulas were isocaloric (67 kcal/100 ml) and contained
bovine milk proteins (40/60 casein/ whey ratio), carbo-
hydrates, namely lactose and maltodextrine, fats (milk
fat, vegetable oils from coconut, sunflower, and soya leci-
thin), vitamins, and minerals in amounts appropriate for
full nutrition of newborn infants up to 6 months of age.
Both formulas contained L. reuteri DSM 17938 at concen-
trations that would deliver approximately 108 colony form-
ing units (CFU) per day. They differed only in the presence
5.5 g/L of GOS and 0.36 g/L of FOS in the experimental
formula without changing the other ingredients. Of note,
total available carbohydrates amounts were similar in the
two formulas.
Formulas were manufactured by Nestlé in Boué, France.
The two formulas were indistinguishable and were sup-
plied in similar cans that were coded with letters and
colors by the study sponsor (Nestlé). The infant formula
were available in powder form and were provided to the
parents during each study visit. Parents, investigator, sup-
port staff, and the clinical project manager were blinded
to the identity of the formulas.
Randomization
An in-house computer program (Trial Balance) was used
to generate a randomization sequence to allocate infants
to the two formula groups. Infants were randomized into
the two groups with a 1:1 ratio with stratification by gen-
der. A probability of <0.8 was used to minimize imbal-
ance. The investigator accessed allocation numbers via a
web-based application.
Trial procedure
Recruited infants were randomly assigned to either the
control or the experimental group after obtaining in-
formed consent from parent/legal guardian. At baseline
(14 days of age) the infants’ birth information (gestational
age and mode of delivery), anthropometric measurements
(weight, length, and head circumference), and medical
history since birth, including any intake of medication,
was recorded. Additionally, the parents’ demographic
data, weight, and height as well as the mothers’ smoking
and drinking habits were also recorded.
At enrollment, parents were given the formulas for
their infants along with preparation instructions. Subse-
quently, the cans were distributed to the patient’s family
according to the randomized code. They were also given
diaries with explanations on how to record daily volume
of formula intake, digestive tolerance, and the occur-
rence of any illness for the 3 days preceding each visit.Infants were fed the study formulas ad libitum from
enrollment to 6 months of age. Visits to the study center
took place within 3 days of age 15 days (0.5 month),
within 5 days of age 30 days (1 month), within 7 days of
age 61 days (2 months), within 7 days of age 122 days
(4 months), and within 7 days of age 182 days (6 month)
of age. At each visit the study investigator examined the
infants, took anthropometric measurements, collected
and reviewed the 3-day diaries, and assessed the occur-
rence of any AEs. Infants with intake of complementary
feeding before 4 months and interrupting study formula
intake before the 4-month visit were considered to have
major protocol deviations. At the 2-month visit, approxi-
mately 10 g of fresh stool samples were collected from
the first 60 infants enrolled in the study who had had no
perinatal antibiotic treatment. The stools were collected
at home within 30 minutes after stool emission and trans-
ferred into a sterile tube. The container was placed in an
aluminium bag as well as a packet of AnaeroGen (Oxoid,
Hampshire U.K) to maintain an anaerobic environment.
The tightly closed bag will be kept refrigerated (4° Celsius)
and transported on ice within 10 hours to the study site.
Fresh urine samples were collected during the study visit
with the clean catch method.
Outcome measures
The primary outcome was change in weight between
birth weight and 4 months in both the control and ex-
perimental arm. All infants were weighed nude on the
same electronic scale to the nearest 10 g. The scale was
calibrated every month according to the manufacturer’s
instructions.
Secondary outcomes were length, BMI, head circumfer-
ence, digestive tolerance, stool bacterial counts, urinary
D- and L-lactate concentrations, and AEs. Recumbent
length was measured to the nearest millimeter on a stan-
dardized length board with the infants’ feet flexed and
with at least two study staff ensuring proper body align-
ment. Head circumference was measured to the nearest
millimeter at approximately 2.5 cm above the eyebrows, at
the largest measurement of the head circumference, using
a standard plastic-coated, non-stretchable measuring tape.
Digestive tolerance was assessed based on stool fre-
quency and consistency, flatulence, restlessness/irritabil-
ity, and frequencies of waking up at night and colic.
Total bacterial, bifidobacteria, lactobacilli, Clostridium,
enteroccci, and Bacteriodes counts were quantified by
fluorescence in situ hybridization (FISH) using probes de-
scribed previously [29-37], and L. reuteri was quantified
by culture plating. For the FISH analysis, 2 g of stool sam-
ples were frozen in cryotubes and stored at −80°C until
further analysis by an external partner (Biovisible, The
Netherlands). For bacterial quantification by culture plat-
ing, approximately 2 g of stool was added to a saline
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in cryotubes at −80°C. Analyses were performed by an ex-
ternal partner (ATT, Piacenza, Italy).
Urine samples were collected at 2 months, and 6-ml
aliquots were placed into cryotubes and frozen immedi-
ately at −40°C until further analysis. Urinary D- and L-
lactate concentrations and creatinine concentrations were
determined at the Centre Hospitalier Universitaire Vaudois
(Lausanne, Switzerland) as described previously [38,39].
Both D- and L-lactate concentrations were normalized
per mole creatinine (mmol lactate/mol creatinine).
Adverse Events (AEs) and Serious Adverse Events (SAEs)
The study investigator evaluated the seriousness of all
AEs and any potential relation to the study products.
AEs and SAEs were coded using the WHO Adverse Re-
actions Terminology (WHO-ART).
Statistical methods
Sample size was calculated based on the primary out-
come of showing non-inferiority in weight gain. The
non-inferiority margin was set at −0.5 standard deviation
(SD) based on the WHO child growth standards. The
type I error (α) was set to 2.5%, power to 80%, and the
common SD to 1.0. The difference in mean weight-for-
age z-score between groups was expected to be 0.0 SD.
Based on a one-sided t-test, 64 infants had to be enrolled
in each group to show a significant difference. Assuming
a 20% dropout rate, 78 infants had to be enrolled in each
group for a total of 156 infants in the study. Sample size
was calculated using NQuery Advisor 7.0.
All randomized infants were included in the intention-
to-treat (ITT) analysis. Infants with major protocol devia-
tions were excluded from the per protocol (PP) analysis.
Data are summarized as mean ± SD or median and inter-
quartile range (IQR).
The primary endpoint was the change in weight-for-age
z-scores between birth and 4 months in the two formula
groups. Non-inferiority in weight was evaluated based on
simultaneous 2-sided 95% CI for the mean weight z-score
in each formula group and the CI for the difference in
mean change between treatment arms. Changes in weight-
for-age z-scores between birth and 4 months were calcu-
lated using a mixed model correcting for gender and birth
weight and with visit as a random effect. Non-inferiority
was established if the lower bound of the one-sided 97.5%
confidence interval (CI) lay above −0.5 SD.
The point estimate for the difference between formula
groups in mean weight-for-age z-score change from birth
to 4 months and the two-sided 95% CI were calculated
using a fitted mixed model. The non-inferiority of the ex-
perimental formula compared with the control formula
was tested using −0.5 SD for the lower bound of the
97.5% CI.Non-inferiority of the experimental formula compared
with the control formula was also determined by compar-
ing mean daily weight gain in g/day. The non-inferiority
margin for the lower bound of the one-sided 97.5% CI for
the difference in mean daily weight gain between the
formula groups was −3.0 g/day. Changes in other an-
thropometric measurements (length, BMI, and head
circumference) between birth and 4 months were com-
pared between groups using a t-test and a mixed model
correcting for gender and birth weight and using visit
time (age) as a random effect.
Formula intake, the various parameters for digestive
tolerance, and the average number of times of waking up
per night were compared between groups using two-sided
t-test. Stool counts per day were calculated for each infant
by summing the total occurrence of stools and dividing it
by the number of days for which it was recorded. To ob-
tain the proportion of a particular stool consistency, the
number of days for which a particular consistency was
predominant was summed up and divided by the total
number of days for which consistency was assessed. Flatu-
lence was considered to have occurred if it occurred ≥2
times per day, irritability if infants cried for ≥3 hours per
day, and colic and spitting up if each occurred ≥1 time per
day. For each of these symptoms, the proportion of days
in which the symptom occurred was the total number of
days in which it occurred divided by the total number of
days it was assessed.
Mean bacterial counts were compared between groups
using a two-sided t-test, with a significance level of 0.05.
The percentage of infants having at least one AE or SAE
during the 6-month study period was compared between
groups using Chi-Square test.
The R statistical package (version 2.13.1) was used in
all analyses.
Results
Demographics and baseline characteristics
One hundred and forty infants were randomized into
the two formula groups and were included in the ITT
population (Figure 1). A total of 17 infants were ex-
cluded from the PP population either because they had
intake of complementary food before 4 months or
because they interrupted intake of the study formula;
therefore 123 infants were included in the PP popula-
tion (Figure 1).
The demographics and baseline characteristics of in-
fants and their parents were balanced between the two
groups, though a higher proportion of households in the
experimental group had a smoker (Table 1).
Weight gain
Mean weight-for age z-scores between birth and 4 months
were above the WHO standards in both formula groups
Figure 1 Infants participating in the study. ITT, intention to treat; PP, per protocol; GOS, galacto-oligosaccharides; FOS, fructo-oligosaccharide.
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birth and 4 months was close to 1 SD in both formula
groups (Table 2). The lower bound of the 95% CI of the
change in weight-for-age z-scores was above −0.5 SD
(relative to WHO standard) in both formula groups in the
ITT and PP populations (Table 2).
Additionally, the lower bound of the 2-sided 95% CI of
the difference in the change in mean weight-for-age z-
scores between the two formula groups was above −0.5
SD in both the ITT and PP populations (Table 2), dem-
onstrating the non-inferiority of the experimental for-





L. reuteri + GOS/
FOS (Experiment)
(N = 72)
Age (days) at recruitment 14.9 (2.1) 14.6 (2.0)
Male 28 (41.18) 30 (41.67)
Gestational Age (weeks)
at birth
38.77 (1.15) 39.19 (1.14)
Vaginal Delivery 53 (77.94) 59 (81.94)
Birth Weight (kg) 3.13 (0.39) 3.19 (0.41)




33.3 (1.3) 33.5 (1.3)
Body Mass Index
(kg/m2)
12.53 (1.07) 12.58 (1.13)
Ethnic Origin: Malay 47 (69.1) 55 (73.4)
Asian 9 (13.2) 8 (11.1)
Other 12 (17.6) 9(12.5)
Households with smoker 41 (61.2) 49 (70.0)
SD, Standard deviation; GOS, Galacto-oligosaccharides;
FOS, Fructo-oligosaccharide.pre-specified margin. Analysis of a mixed model con-
firmed no significant treatment effect (p = 0.755).
Infants in the experimental group had slightly greater
mean weight gain compared with those in the control
group (31.8 g/day vs. 30.6 g/day). However, the differ-
ence in mean daily weight gain in g/day was not signifi-
cantly different between the two groups (Table 2).Changes in other anthropometric measurements
Changes in length, head circumference, and BMI between
birth and 4 months were not significantly different be-
tween the two groups; though BMI tended to be higher in
the experimental group (Table 3).Formula intake and digestive tolerance
Mean daily formula intake was not significantly different
between the two groups at any time during the study,
though overall intake seemed to be greater in the experi-
mental group throughout the study (Figure 2). Other
than liquid stools, which occurred more frequently in
the experimental group (Table 4), other parameters for
digestive tolerance showed no significant difference that
would indicate reduced tolerance for the experimental
formula (Table 4).Stool bacterial counts
Median bifidobacterial counts were about half a log higher
in the experimental group (Table 5), and they made up a
larger proportion of the stool bacterial population in the
experimental group (83.8%) as compared with the control
group (39%). Median counts of other bacteria as well as
their proportions of the total bacterial counts were com-
parable between the two groups (Table 5).
Table 2 Mean weight gain between birth and 4 months
L. reuteri (control) L. reuteri + GOS/FOS (experimental) Difference between control
and experimental
ITT N = 68 N = 72
z-score (95% CI) +0.82 (0.53 to 1.10) +0.91 (0.63 to 1.20) +0.10 (−0.31 to 0.50)
g/day (SD) 30.61 (6.5) 31.84 (7.4) P = 0.302
PP N = 61 N = 62
z-score (95% CI) +0.92 (0.62 to 1.22) +0.93 (0.63 to 1.23) +0.01 (−0.41 to 0.43)
GOS, Galacto-oligosaccharides; FOS, Fructo-oligosaccharide; ITT, Intention-to-treat; CI, Confidence interval; PP, Per protocol.
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Mean (± SD) D-lactate concentrations in the experimental
(4.0 ± 5.4 mmol/mol creatinine) and the control groups
(3.1 ± 3.1 mmol/mol creatinine) were not significantly dif-
ferent (t-test, p = 0.46). Similarly, mean (± SD) L-lactate
concentrations (58.6 ± 58.0 and 66.2 ± 86.9 mmol/mol
creatinine in the experimental and the control groups, re-
spectively) were not significantly different between the
two groups (t-test, p = 0.69).AEs
Fifty-two infants (76.5%, ITT) in the control group and
53 (73.6%, ITT) in the experimental group had at least
one AE during the study (Chi square P > 0.5). The most
frequent AEs (by system organ class) in both groups
were upper respiratory tract infections (45% of infants),
respiratory system disorders (26% of infants), skin and
appendages disorders (16% of infants), general disor-
ders (14%), and resistance mechanism disorders (10%).
Slightly more infants in the experimental group had
gastro-intestinal (GI) system disorders and skin and
appendages disorders (8% and 19%, respectively) com-
pared with those in the control group (6% and 13%, re-
spectively). More infants in the control group (13%)
had resistance mechanism disorders compared withTable 3 Change in length, head circumference, and BMI













+0.70 (0.114) +0.72 (0.134) 0.332
BMI kg/m2 3.69 (1.327) 4.0 (1.940) 0.281
*t-test; BMI, Body mass index; ITT, Intention-to-treat; SD, Standard deviation;
GOS, Galacto-oligosaccharides; FOS, Fructo-oligosaccharide.those in the experimental (7%). None of these differ-
ences were statistically significant.
SAEs (comprising hospitalization for various infec-
tions) were reported in five (7.4%) infants in the L.
reuteri group and 10 (13.9%) infants in the experi-
mental group (Chi Square, P = 0.28). The number of
SAE events reported were 7 out of 68 control infants
and 14 out of 72 experimental infants were also not
significant (Chi Square, P = 0.16) (Table 6). None of
the AEs or SAEs was reported to be related to the
study formulas.Discussion
Formulas containing synbiotics are thought to have
more beneficial properties than those containing pro-
biotics or prebiotics separately [26]. Even though no
safety or tolerance issues with the use of either pro-
biotics or the prebiotics GOS and FOS have been re-
ported in healthy term infants, because of the paucity
of studies with synbiotics, the ESPGHAN committee
on Nutrition has reiterated the need for well-
conducted clinical trials evaluating the safety and effi-
cacy of synbiotic products [40].
L. reuteri has been evaluated in clinical trials in in-
fants with no reported safety issues [10,12,26]. Simi-
larly, the safety of the prebiotic GOS/FOS mixture
has also been accepted and is authorized for use in
infant formulas. At the initiation of our study, the
safety of the mix of L. reuteri and GOS/FOS for in-
fants had not, to our knowledge, been studied. The
aim of the current study was to evaluate the safety of
a formula containing L. reuteri and GOS and FOS in
healthy term infants.
Our study showed that weight gain between birth
and 4 months in healthy term infants fed experimen-
tal infant formula containing L. reuteri + GOS/FOS
was not inferior to the WHO standards nor to that
of infants fed a control formula containing only L.
reuteri, indicating the safety of the synbiotic formula
with respect to its nutritive value and tolerance data.
Figure 2 Mean daily volume of formula intake. Error bars indicate standard deviation. GOS, galacto-oligosaccharides; FOS, fructo-oligosaccharide.
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circumference gains, between birth and 4 months
nor changes in BMI between birth and 4 months
showed any significant difference between the two
formula groups in this study. Volume of formula in-
take tended to be slightly higher in the experimental
group throughout the study. This may have partly
contributed to the higher, but statistically non-
significant, weight gain in infants fed the experimen-
tal formula.
Overall, there were no differences in GI symptoms
among infants consuming the two formulas, indicat-
ing a good tolerance of the synbiotic formula. The
frequency of colic and waking up at night, which
could be indications of GI discomfort, were infre-
quent and similar in both groups. In a study pub-
lished recently we showed that infants fed a controlTable 4 Measures of digestive tolerance during the first 4 mo
L. reuteri (control)
N Mean (SD) daily frequency
Stool Frequency 61 4.84 (6.06)
Hard stools 61 0.42 (1.81)
Liquid stools 61 0.11 (0.39)
Flatulence 61 0.91 (0.20)
Irritability 30 0.02 (0.04)
Spitting 42 0.75 (1.14)
Colic 14 0.26 (0.19)
Waking up 61 1.94 (0.74)
*two-sided t-test; ITT, Intention-to-treat; GOS, Galacto-oligosaccharides; FOS, Fructo-formula or a formula containing L. reuteri woke up
approximately twice nightly [14], consistent with the
current study. Furthermore, although infants on the
synbiotic formula were more likely to have loose
stools, daily stool output was similar between both
groups. This GI symptom is consistent with the ef-
fect of GOS and FOS previously described, and is
also commonly seen among breast-fed infants
[41-44]. None of the infants in the study required
hospital admission for diarrheal illness.
Both the bifidobacterial counts and the relative
proportion of bifidobacteria in stool were higher in
the experimental group compared with the control
group, consistent with the bifidogenic effect of GOS
and FOS previously reported [44,45]. Counts of the
other bacterial species in the two groups were within
half a log of each other.nths, ITT
L. reuteri + GOS/FOS (experimental) P-value*
N Mean (SD) daily frequency
62 6.06 (7.52) 0.323
62 0.13 (0.81) 0.256
62 0.43 (0.92) 0.014
62 0.93 (0.18) 0.561
25 0.02 (0.04) 1.000
43 0.65 (0.74) 0.566
15 0.33 (0.33) 0.152
62 2.09 (0.59) 0.217
oligosaccharide; SD, Standard deviation.
Table 5 Stool bacterial counts (CFU/g) at 2 months
L. reuteri (control) L. reuteri + GOS/FOS (experimental) Comparison of bacterial
counts between groups*
N (% BDL)† Median (IQR) N (% BDL)† Median (IQR)
Total bacterial count 32 (0) 2.4 × 1010 (1.7 × 1010) 29 (0) 3.7 × 1010 (3.2 × 1010) 0.01
Lactobacillus reuteri 32 (0) 9.5 × 106 (1.5 × 107) 29 (3.45) 1.5 × 107 (4.3 × 107) 0.118
Bifidobacteria 32 (0) 9.4 × 109 (1.3 × 1010) 28 (3.45) 3.1 × 1010 (2.4 × 1010) 0.00
Lactobacilli and
Enterobacteria
28 (12.5) 5.2 × 107 (8.5 × 107) 26 (10.34) 1.0 × 108 (1.9 × 108) 0.07
Enterobacteria 32(0) 5.1 × 108 (6.5 × 108) 29 (0) 7.6 × 108 (8.4 × 108) 0.132
Clostridia 21 (34.38) 4.8 × 108 (9.3 × 108) 14 (51.72) 2.6 × 108 (1.7 × 109) 0.752
*Two-sided t-test; †Number of samples analyzed and proportion below detection limit (BDL); CFU, Colony forming unit; IQR, Interquartile range.
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SAE compared with the control group, these did not ap-
pear to be related to the formula, nor were the differ-
ences significant. All SAEs were related to short
duration hospitalizations and none of the infants died or
had long term harm or disability as a result of an SAE.
All children had a clinical review post SAE and all had
recovered well subsequently. Additionally none of the
infants had diarrhea, and none of the SAEs (except a
case of vomiting in the L. reuteri group) were related to
the GI system.Table 6 Number of Serious Adverse Events (SAEs)*
reported during the study, Intention-to-Treat
SAE preferred term** L. reuteri (control)
(N = 68)
L. reuteri + GOS/
FOS (experimental)
(N = 72)
Total number of SAEs 7 14
Infection Viral 1 0
Influenza-Like Symptoms 1 0
Pneumonia (CXR/bacterial) 2 3
Vomiting 1 0
Varicella Zoster infection 1 0
Choking 1 0










Rash Erythematous 0 1
Bronchitis 0 1
Apnoea Neonatal 0 1
Pharyngitis 0 1
*Some infants had >1 SAE; **Coded according to World Health Organization
Adverse Reactions Terminology.Conclusions
The synbiotic experimental formula containing L. reu-
teri +GOS/FOS was safe and well-tolerated in healthy
term infants. Growth of infants consuming the synbiotic
formula was not inferior to WHO growth standards or
to that of infants consuming the formula containing only
the probiotic.
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